Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early-phase study of 64Cu-PD-32766 PET in clear cell renal cell carcinoma
jRCTs031240046Completed
- Sponsor
- PeptiDream Inc.
- Start
- May 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of PD-32766 in clear cell renal cell carcinoma (ccRCC), sponsored by PeptiDream Inc. Primary endpoint: Per-patient PET sensitivity. Started May 2024; status: completed.
02
Drugs
PD-32766
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on jRCTs031240046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240046.